PEGASUS-TIMI 54 Long-term DAPT Benefit Index (PEGASUS DAPT Benefit Calculator)
Patient characteristics
Enter clinical features to assess the PEGASUS-TIMI 54 trial phenotype.
How to interpret this assessment
PEGASUS-TIMI 54 studied stable patients aged 50 years or older with a spontaneous MI 1–3 years earlier and at least one additional high-risk feature: age ≥65 years, diabetes requiring medication, a second prior spontaneous MI, multivessel coronary disease, or Cockcroft–Gault CrCl <60 mL/min.
What the numbers mean
- Eligibility phenotype: a checklist approximation of key trial entry features; it is not a treatment recommendation.
- ARR: difference between the trial's 3-year placebo and ticagrelor 60 mg event estimates for CV death, MI, or stroke.
- NNT: approximate number treated for the trial follow-up to prevent one primary efficacy event, based on the absolute difference.
- Bleeding trade-off: TIMI major bleeding was more frequent with ticagrelor. Individual bleeding risk and contraindications require a separate assessment.
Clinical considerations
Before considering prolonged DAPT, assess ischemic risk, bleeding history, concomitant anticoagulants, prior stroke or intracranial bleeding, renal and hepatic status, drug tolerance/interactions, patient preferences, and current guideline recommendations. Do not use the trial-average ARR/NNT as a personalized prediction.
Evidence and references
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.